Aug 01, 2022
Candel Therapeutics Appoints Three New Members to its Board of Directors
Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO Joseph Papa, Chief Executive Officer of Bausch + Lomb Corporation Renee Gaeta, Chief Financial Officer of Eko Devices NEEDHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late
Additional Formats
May 26, 2022
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entry Durable disease stabilization that was ongoing at data cutoff in 62.5 percent of the patients who entered the study with progressive disease and were followed for a minimum of 12
Additional Formats
Feb 03, 2022
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Francesca Barone, M.D., Ph.D., has been named as the company’s Chief Scientific Officer.
Additional Formats
Displaying 1 - 10 of 11